BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5699
- TODAY'S CHANGE (%)-0.0001 (-0.0175%)
- Bid / Lots0.5511/ 1
- Ask / Lots0.6000/ 360
- Open / Previous Close0.5629 / 0.5700
- Day Range
- 52 Week Range
- Volume276,846
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 1728 | 0.5629 |
| 09:34 ET | 4720 | 0.5625 |
| 09:36 ET | 263 | 0.57 |
| 09:38 ET | 700 | 0.57 |
| 09:39 ET | 600 | 0.57 |
| 09:41 ET | 680 | 0.5728 |
| 09:43 ET | 3400 | 0.5611 |
| 09:48 ET | 2800 | 0.5611 |
| 10:01 ET | 179 | 0.5796 |
| 10:03 ET | 500 | 0.5797 |
| 10:12 ET | 17200 | 0.565 |
| 10:14 ET | 35200 | 0.565 |
| 10:15 ET | 8900 | 0.565 |
| 10:19 ET | 1809 | 0.5611 |
| 10:30 ET | 2500 | 0.5607 |
| 10:33 ET | 280 | 0.5749 |
| 10:44 ET | 1000 | 0.561101 |
| 10:46 ET | 11000 | 0.5611 |
| 10:53 ET | 900 | 0.5611 |
| 10:57 ET | 200 | 0.5602 |
| 11:09 ET | 528 | 0.5608 |
| 11:18 ET | 587 | 0.57 |
| 11:20 ET | 900 | 0.568 |
| 11:22 ET | 251 | 0.5679 |
| 11:24 ET | 1500 | 0.5659 |
| 11:26 ET | 100 | 0.5649 |
| 11:29 ET | 33464 | 0.5612 |
| 11:33 ET | 1640 | 0.5613 |
| 11:58 ET | 33935 | 0.5612 |
| 12:05 ET | 12000 | 0.5612 |
| 12:21 ET | 42116 | 0.56 |
| 12:32 ET | 600 | 0.567 |
| 12:34 ET | 4100 | 0.567699 |
| 12:43 ET | 200 | 0.5676 |
| 12:45 ET | 400 | 0.5675 |
| 12:48 ET | 4600 | 0.5602 |
| 12:52 ET | 100 | 0.5653 |
| 12:54 ET | 100 | 0.5675 |
| 12:57 ET | 231 | 0.5674 |
| 12:59 ET | 900 | 0.5674 |
| 01:01 ET | 200 | 0.5674 |
| 01:06 ET | 2500 | 0.5637 |
| 01:08 ET | 100 | 0.56694 |
| 01:15 ET | 200 | 0.5673 |
| 01:26 ET | 26400 | 0.5674 |
| 01:28 ET | 600 | 0.575 |
| 01:42 ET | 100 | 0.57 |
| 01:44 ET | 338 | 0.5713 |
| 01:48 ET | 220 | 0.5749 |
| 01:51 ET | 540 | 0.571 |
| 02:00 ET | 100 | 0.571 |
| 02:08 ET | 600 | 0.5711 |
| 02:09 ET | 5700 | 0.565951 |
| 02:24 ET | 100 | 0.5748 |
| 03:02 ET | 1800 | 0.5675 |
| 03:56 ET | 1428 | 0.5699 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 48.9M | -0.7x | --- |
Marker Therapeutics Inc | 48.4M | -3.9x | --- |
LAVA Therapeutics NV | 47.3M | -1.7x | --- |
Cue Biopharma Inc | 60.3M | -1.2x | --- |
Lipocine Inc | 44.1M | -4.8x | --- |
Palatin Technologies Inc | 31.5M | -0.8x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.9M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
